Lineage Cell Therapeutics (LCTX) Divestments (2018)

Lineage Cell Therapeutics (LCTX) reported Divestments of $3.2 million for Q1 2018.

Lineage Cell Therapeutics (LCTX) Divestments (2018) Analysis & Trends

Lineage Cell Therapeutics has reported Divestments for 1 years, with the latest figure at $3.2 million in Q1 2018.

For the quarter ending Q1 2018, Divestments changed N/A year-over-year to $3.2 million; the trailing twelve-month figure through Dec 2018 stood at $3.2 million (changed N/A YoY), and the FY2018 full-year result was $3.2 million, changed N/A from the prior year.
Divestments for Q1 2018 stood at $3.2 million.
The five-year high for Divestments was $3.2 million in Q1 2018, with the low at $3.2 million in Q1 2018.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Divestments (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Lineage Cell Therapeutics	303.84 Mn	239.94 Mn	1.73 Mn	-

Historic Data

Download Data

Date	Value
Mar 31, 2018	3.22 Mn